Preventive Application of Letrozole Decrease Incidence of Early Onset of OHSS
Phase 4
Completed
- Conditions
- Ovarian Hyperstimulation Syndrome
- Interventions
- Registration Number
- NCT02670304
- Lead Sponsor
- First Affiliated Hospital, Sun Yat-Sen University
- Brief Summary
Letrozole is one kind of aromatase inhibitors which may have effect on decrease estrogen in luteal phase and inhibit the luteal function of ovary. In 2009, Letrozole was reported as one candidate for the treatment or prevention of ovarian hyperstimulation syndrome.
- Detailed Description
Letrozole was proved to be effective in decreasing the estradiol level of luteal phase after ovum picked up. In this randomized controlled study, investigators try to observe the effectiveness of letrozole on decreasing the incidence of early ovarian hyperstimulation syndrome and vascular epithelium growth factor level of women with high ovarian hyperstimulation syndrome risks.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Female
- Target Recruitment
- 100
Inclusion Criteria
- infertile women undergoing IVF treatment with more than 25 oocytes collected.
Exclusion Criteria
- letrozole contraindications,e.g. severe hepatic and renal dysfunction
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description letrozole letrozole letrozole for the first day after ovum picked up at least for 5 days. aspirin Aspirin asprin for the first day after ovum picked up at least for 5 days.
- Primary Outcome Measures
Name Time Method incidence of early OHSS up to 1 months
- Secondary Outcome Measures
Name Time Method vascular endothelial growth factor level up to 1 months vascular endothelial growth factor in pg/ml
incidence of hydrothorax up to 1 months incidence of liver dysfunction up to 1 months incidence of renal dysfunction up to 1 months incidence of electrolytic imbalance up to 1 months incidence of hemoconcentration up to 1 months incidence of elevated WBC up to 1 months